RecruitingPhase 4NCT05309460

Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial

Sponsor

Nebraska Methodist Health System

Enrollment

600 participants

Start Date

Jun 20, 2022

Study Type

INTERVENTIONAL

Conditions

Randomized trial comparing risk of hospital readmission and hypertensive complications between patients managed on Labetalol compared to Nifedipine.

Sex: FEMALEMin Age: 19 Years

Any patient admitted for delivery by cesarean or vaginal delivery at 24 weeks gestation or greater with hypertension(HTN). Hypertension will be defined during the study as either a systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90mmHg on two occasions at least 4 hours apart. This definition is consistent with the ACOG definition for pregnancy related HTN. Following enrollment, treatment will be escalated at discretion of primary provider with the goal of normotension.

History of moderate persistent asthma, coronary artery disease, heart failure, AV heart block, pulmonary edema
Contraindication to either Nifedipine or Labetalol
HR \<60 or \>110
Native language other than English or Spanish